Drug Profile
Research programme: inflammation therapy - Kowa
Latest Information Update: 30 Mar 2007
Price :
$50
*
At a glance
- Originator Kowa
- Developer University of Edinburgh; University of Glasgow; University of Paisley; University of Strathclyde
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Dermatitis; Inflammatory bowel diseases; Pancreatitis; Psoriasis
Most Recent Events
- 17 May 2006 No development reported - Preclinical for Crohn's disease in Scotland (unspecified route)
- 17 May 2006 No development reported - Preclinical for Dermatitis in Scotland (unspecified route)
- 17 May 2006 No development reported - Preclinical for Inflammatory bowel disease in Scotland (unspecified route)